Carisbamate
Complex Partial Epilepsy
SK Life Science, Inc.Small moleculePhase 3Dormant
BB
71/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 59/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Complex Partial Epilepsy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pregabalin Northeast Regional Epilepsy Group | Phase 4 | BBB |
Rwj-333369 SK Life Science, Inc. | Phase 3 | BB |
Gabapentin Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 4 | BB |
Zonisamide Eisai Inc. | Phase 3 | B |
Diazepam Pfizer | Phase 3 | B |
Ganaxolone Marinus Pharmaceuticals | Phase 2 | B |
Bis-001 Er Supernus Pharmaceuticals, Inc. | Phase 1 | CC |
Same molecule, other indications
Carisbamate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →